Michael J. Kennelly, MD, FPMRS, FACS

Panelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.

In this discussion, Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber share their approaches to post-procedure care and follow-up for overactive bladder (OAB) treatments. They detail the patient experience immediately after the procedure, the role of nursing and support staff, and methods for guiding patients through the recovery process, including managing potential complications and effective communication strategies. Additionally, they address challenges in patient adherence to follow-up visits, share insights on assessing treatment effectiveness during these visits, and discuss their strategies for enhancing patient engagement and satisfaction in their practices.

In this episode, Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber discuss their strategies for ensuring patient comfort during overactive bladder (OAB) treatment procedures. They delve into the roles of clinical staff, the setup of the procedure room, and how they address patient needs and concerns to create a reassuring environment. The experts also share their experiences in handling challenges during procedures, illustrating how they've adapted their practices based on patient feedback to maintain a patient-centric focus throughout the treatment process.

Panelists discuss the importance of patient-centric approaches in the procedural treatment of overactive bladder (OAB). They share their practices in preparing patients for procedures, including patient education, shared decision-making, and tailoring pre-procedure instructions, with a focus on managing patient expectations and addressing fears. The episode emphasizes the role of the clinical team in ensuring patient comfort, highlighting practical considerations, real-world experiences, and best practices for optimizing patient-centered care in OAB management.

Experts share their long-term clinical experiences with intravesical botulinum toxin type A therapy, particularly emphasizing quality of life, patient satisfaction, simplicity, safety, and the comfort patients find in its non-permanent nature.

In this insightful episode, Dr. Kennelly engages with Dr. Eilber and Dr. Benson in a comprehensive discussion of sacral neuromodulation and transcutaneous and posterior tibial nerve stimulation therapies used in the treatment of OAB, including their mechanisms, patient reception of FDA-approved devices, overall evolution and current practices implementation in clinical settings.

Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber share their experiences in the use of intravesical botulinum toxin type A as a treatment option for overactive bladder (OAB) into treatment plans. They provide insight into identifying optimal candidates, the outcomes they have observed, and benefits and risks, including strategies for managing these risks. They explore the decision-making process in guiding patients through various treatment options, considering individual lifestyles and preferences.

In this episode, Dr. Kennelly, alongside Dr. Eilber and Dr. Benson, explores the advancements of transcutaneous and posterior tibial nerve stimulation (TTNS and PTNS) and sacral neuromodulation (SNM). The episode sheds light on how these therapies fit into current medical practices, their effectiveness, and the convenience they offer to patients. The specialists consider patient preferences and compliance challenges in choosing the right therapy. The episode provides a comprehensive understanding of how these therapies fit into patient-centric management plans, offering valuable insights for both patients and healthcare professionals.

In this insightful episode, Dr. Kennelly, along with Dr. Eilber and Dr. Benson, discuss the transition from pharmacologic treatments to third-line therapies for overactive bladder, focusing on the mechanism of action of various neuromodulation methods and benefits they offer to patients seeking sustainable solutions for OAB management.

Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber discuss the goals and assessment methods for overactive bladder (OAB) pharmacological treatments, including how they monitor and address refractory or nonresponsive cases. They explore the real-world rates of medication failure, particularly with anticholinergics, and delve into the decision-making process behind considering alternative therapies, focusing on factors that prompt a change in treatment, especially for specific patient populations. The discussion includes insights on when and why to shift from standard OAB medications to other therapeutic options.

In this episode, experts review safety concerns, drug interactions, and common adverse effects (AEs) associated with overactive bladder (OAB) medications. They discuss the impact of AEs like constipation, hypertension, and dry mouth on patient quality of life, strategies for managing these effects, and circumstances warranting a change in treatment. The experts also examine recent clinical evidence linking anti-cholinergic treatments to an increased risk of dementia in older patients, discussing its implications for clinical practice and strategies for urologists to remain vigilant about such safety concerns.

Experts explore the clinical benefits and limitations of standard pharmacological options, like anti-muscarinic agents and beta-3 adrenergic agonists, and share their preferences and experiences in selecting and managing treatments for OAB, focusing on the effectiveness and patient-specific considerations in their clinical practice. In this episode, Dr. Kennelly, alongside Drs. Eilber and Benson, discusses the transition to second-line therapies for overactive bladder, focusing on medication classes like anticholinergics and beta-3 agonists. They explore patient-centered considerations such as medication compliance, cost, insurance coverage, and the chronic nature of overactive bladder management, emphasizing individualized treatment based on patient needs and health profiles.

Expert panelists review the AUA/SUFU guidelines for overactive bladder (OAB) treatment, discussing first-line behavioral strategies and the transition to pharmacological treatments.

Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber delve into the significant impact of OAB on patients' quality of life, including its effects on daily activities and mental well-being, and how this burden shapes clinical decisions in the early stages of treatment and selection of appropriate therapeutic options.

In this Urology Times® episode, Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber discuss overactive bladder (OAB), focusing on its diagnosis, symptomatology, and patient populations most at risk, including gender and age-related factors.